Shareholders that lost money on Marinus Pharmaceuticals, Inc.(MRNS) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More

Core Viewpoint - A class action securities lawsuit has been filed against Marinus Pharmaceuticals, Inc. for alleged securities fraud affecting investors between March 17, 2021, and May 7, 2024 [1][2]. Group 1: Lawsuit Details - The complaint alleges that defendants made false statements regarding the risk of failing to meet early-stopping criteria in the Randomized Therapy in Status Epilepticus Trial (RAISE) [2]. - It is claimed that defendants did not disclose that failing to meet the early stopping criteria in the RAISE trial could lead to the cessation of the separate Phase 3 RAISE II trial [2]. - As a result, the statements made by defendants about Marinus' business, operations, and prospects were materially false and misleading [2]. Group 2: Next Steps for Investors - Investors who suffered losses in Marinus during the relevant time frame have until August 5, 2024, to request the Court to appoint them as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff to share in any potential recovery [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has a strong track record in high-stakes securities litigation [4]. - The firm has over 70 employees dedicated to serving clients and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].